Celldex Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.59) Per Share (NASDAQ:CLDX)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Analysts at HC Wainwright lifted their Q2 2024 EPS estimates for Celldex Therapeutics in a note issued to investors on Tuesday, May 7th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($0.59) per share for the quarter, up from their prior estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.85) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q3 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.60) EPS, FY2024 earnings at ($2.34) EPS and FY2025 earnings at ($2.67) EPS.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The company had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $1.20 million.

A number of other equities analysts have also recently weighed in on CLDX. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Guggenheim raised their price target on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $66.00.

Celldex Therapeutics Trading Down 0.4 %

NASDAQ CLDX opened at $41.06 on Thursday. The stock has a market cap of $2.30 billion, a PE ratio of -14.11 and a beta of 1.60. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18. The stock has a fifty day simple moving average of $41.57 and a 200-day simple moving average of $37.05.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Teacher Retirement System of Texas lifted its stake in Celldex Therapeutics by 4.8% in the third quarter. Teacher Retirement System of Texas now owns 11,400 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 522 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Celldex Therapeutics by 70.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 805 shares during the last quarter. New York State Common Retirement Fund lifted its position in shares of Celldex Therapeutics by 3.6% during the 3rd quarter. New York State Common Retirement Fund now owns 23,780 shares of the biopharmaceutical company’s stock worth $654,000 after purchasing an additional 821 shares during the last quarter. Swiss National Bank grew its stake in shares of Celldex Therapeutics by 1.0% during the third quarter. Swiss National Bank now owns 88,300 shares of the biopharmaceutical company’s stock worth $2,430,000 after purchasing an additional 900 shares in the last quarter. Finally, Fisher Asset Management LLC increased its holdings in Celldex Therapeutics by 4.6% in the fourth quarter. Fisher Asset Management LLC now owns 21,492 shares of the biopharmaceutical company’s stock valued at $852,000 after buying an additional 954 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.